TREM-1, TREM-2 and their association with disease severity in patients with COVID-19.
COVID-19
TREM-1
TREM-2
disease severity
Journal
Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
Delayed diagnosis and inadequate treatment caused by limited biomarkers are associated with the outcomes of COVID-19 patients. It is necessary to identify other promising biomarkers and candidate targets for defining dysregulated inflammatory states. The triggering receptors expressed on myeloid cell (TREM)-1 and TREM-2 expression from hospitalized COVID-19 patients were characterized using ELISA and flow cytometry, respectively. Their correlation with disease severity and contrast with the main clinical indicators were evaluated. Increased expression of soluble TREM-1 and TREM-2 in the plasma of COVID-19 patients was found compared to the control group. Moreover, membrane-bound TREM-1 and TREM-2 expression was upregulated on the cell surface of circulating blood T cells from COVID-19 patients. Correlation analysis showed that sTREM-2 levels were negatively correlated with PaO TREM-2 and TREM-1 are critical host immune factors that response to SARS-COV-2 infection and could serve as potential diagnostic biomarkers and therapeutic targets for COVID-19. The expression of soluble TREM-1 and TREM-2 in plasma and membrane-bound TREM-1 and TREM-2 on the cell surface was upregulated in COVID-19 patients.sTREM-2 level was negatively correlated with PaO
Sections du résumé
BACKGROUND
Delayed diagnosis and inadequate treatment caused by limited biomarkers are associated with the outcomes of COVID-19 patients. It is necessary to identify other promising biomarkers and candidate targets for defining dysregulated inflammatory states.
METHODS
The triggering receptors expressed on myeloid cell (TREM)-1 and TREM-2 expression from hospitalized COVID-19 patients were characterized using ELISA and flow cytometry, respectively. Their correlation with disease severity and contrast with the main clinical indicators were evaluated.
RESULTS
Increased expression of soluble TREM-1 and TREM-2 in the plasma of COVID-19 patients was found compared to the control group. Moreover, membrane-bound TREM-1 and TREM-2 expression was upregulated on the cell surface of circulating blood T cells from COVID-19 patients. Correlation analysis showed that sTREM-2 levels were negatively correlated with PaO
CONCLUSION
TREM-2 and TREM-1 are critical host immune factors that response to SARS-COV-2 infection and could serve as potential diagnostic biomarkers and therapeutic targets for COVID-19.
The expression of soluble TREM-1 and TREM-2 in plasma and membrane-bound TREM-1 and TREM-2 on the cell surface was upregulated in COVID-19 patients.sTREM-2 level was negatively correlated with PaO
Autres résumés
Type: plain-language-summary
(eng)
The expression of soluble TREM-1 and TREM-2 in plasma and membrane-bound TREM-1 and TREM-2 on the cell surface was upregulated in COVID-19 patients.sTREM-2 level was negatively correlated with PaO
Identifiants
pubmed: 37848000
doi: 10.1080/07853890.2023.2269558
pmc: PMC10583614
doi:
Substances chimiques
Triggering Receptor Expressed on Myeloid Cells-1
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
Biomarkers
0
C-Reactive Protein
9007-41-4
Procalcitonin
0
Interleukin-6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2269558Références
PLoS Pathog. 2020 May 13;16(5):e1008543
pubmed: 32401783
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2020 Jul;92(7):856-862
pubmed: 32281668
J Infect. 2021 Jun;82(6):e24-e26
pubmed: 33745917
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Intensive Care Med. 2009 Apr;35(4):587-95
pubmed: 18936908
Nat Rev Immunol. 2023 Sep;23(9):580-594
pubmed: 36750615
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32706339
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34185704
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Mol Cell Biochem. 2014 Sep;394(1-2):155-61
pubmed: 24916365
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Front Microbiol. 2022 Mar 03;13:821066
pubmed: 35308376
Regul Pept. 2011 Feb 25;167(1):56-64
pubmed: 21130121
Cell Immunol. 2020 Jun;352:104078
pubmed: 32164997
Clin Rev Allergy Immunol. 2023 Feb;64(1):33-65
pubmed: 35040086
J Infect. 2015 Dec;71(6):706-9
pubmed: 26384438
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Cell. 2021 Apr 1;184(7):1895-1913.e19
pubmed: 33657410
Mol Neurodegener. 2017 Aug 2;12(1):56
pubmed: 28768545
Mediators Inflamm. 2020 May 14;2020:9501617
pubmed: 32508528
J Exp Med. 2015 May 4;212(5):681-97
pubmed: 25897174
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Sci Adv. 2021 Dec 10;7(50):eabi6802
pubmed: 34878838
Cell. 2020 Jun 11;181(6):1207-1217
pubmed: 32531244
Lancet Respir Med. 2022 Sep;10(9):863-876
pubmed: 35568052
Crit Rev Microbiol. 2021 May;47(3):290-306
pubmed: 33522328
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1767-1776
pubmed: 28516200
Nat Immunol. 2006 Dec;7(12):1266-73
pubmed: 17110943
Nature. 2021 Dec;600(7889):408-418
pubmed: 34880490
Signal Transduct Target Ther. 2020 Aug 14;5(1):156
pubmed: 32796814
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Clin Invest. 2021 Sep 1;131(17):
pubmed: 34623322
Crit Rev Microbiol. 2022 Nov 20;:1-19
pubmed: 36403150
Nat Rev Microbiol. 2023 Mar;21(3):133-146
pubmed: 36639608
J Leukoc Biol. 2013 Feb;93(2):209-15
pubmed: 23108097
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1796-1800
pubmed: 32506122